Technology
Health
Medical
Atossa Genetics
$2.549876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$2.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.02 (0.79%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ATOS and other stocks, options, ETFs, and crypto commission-free!
About
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. Read More The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
Employees
4
Headquarters
Seattle, Washington
Founded
2008
Market Cap
23.17M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
1.11M
High Today
$2.56
Low Today
$2.45
Open Price
$2.50
Volume
69.53K
52 Week High
$7.39
52 Week Low
$0.80
Collections
Technology
Health
Medical
Cancer Prevention
Pharmaceutical
Therapy
US
North America
News
NasdaqApr 25
Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit
Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit SEATTLE, April 25, 2019 (GLOBE NEWSWIRE) -- Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that today Steven C. Quay, M.D., Ph.D., Atossa's President and CEO, is providing an update on the Company's clinical programs at the Precision: Breast Cancer World R&D Summit at...
Markets InsiderApr 23
6 Top Gainers In Healthcare Sector (ATOS, AKTX, ATHX...)
(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector. 1. Atossa Genetics Inc. (ATOS) Atossa Genetics is a clinical-stage biopharmaceutical company developing novel therapeutics for breast cancer and other breast conditions. Gained 22.97% to close Tuesday's (Apr.23) trading at $3.48. News: No news Pipeline: Atossa has two development programs: Endoxifen (topical and oral forms) and a program for the targeted delivery of drugs and immunotherapies via its proprietary int...
Seeking AlphaApr 23
Atossa up 27% ahead of Endoxifen presentation
Nano cap Atossa Genetics (ATOS +26.9% ) is up on more than 80% higher volume in the early going. Shares have rallied 41% since Friday. On Thursday, April 25, President & CEO Steven Quay, M.D., Ph.D. will deliver a presentation at the Precision: Breast Cancer World R&D Summit in Boston titled "A Twenty-First Century Approach: From Primary Prevention to Intraductal Immunotherapy" that should include the company's development plan and outlook for endoxifen....
Price Paid on Robinhood
36% Lower
Right Now
52 Week Low
$0.80
Average Price Paid
$3.94
52 Week High
$7.39
Earnings
-$2.90
-$1.93
-$0.97
$0.00
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.63 per share
Actual
-$0.62 per share